Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 790 across all filing types
Latest filing 2026-03-13 Regulatory Filings
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Ytterligare en terbinafin-leverantör godkänd
Regulatory Filings Classification · 95% confidence The document is a press release from Moberg Pharma AB announcing the regulatory approval of an additional supplier for their drug MOB-015. It is a corporate announcement regarding operational/regulatory status rather than a financial report, dividend notice, or management change. Since it does not fit into specific categories like M&A, legal proceedings, or share transactions, it falls under the general regulatory announcement category.
2026-03-13 Swedish
Earnings Release 2025
Earnings Release Classification · 95% confidence The document is titled 'Bokslutskommuniké 2025' (Year-end Report 2025) for Moberg Pharma AB. It contains detailed financial highlights for the full year and the fourth quarter of 2025, including income statements, EBITDA, EBIT, and earnings per share. It also includes a CEO commentary, business updates, and operational performance metrics. This is a comprehensive financial report for a specific period (full year/quarterly), which fits the definition of an Interim/Quarterly Report (IR) in the context of financial reporting cycles. Q4 2025
2026-02-17 Swedish
Audit Report / Information 2025
Audit Report / Information Classification · 95% confidence The document is a 'Year-end report 2025' for Moberg Pharma AB. It contains detailed financial highlights for the full year and the fourth quarter, CEO comments, business strategy, and operational updates. It is a comprehensive report covering the company's performance for the fiscal period, which fits the definition of an Interim/Quarterly Report (IR) as it covers the year-end period and provides detailed financial and operational results. FY 2025
2026-02-17 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – september 2025' (Interim Report January – September 2025) for Moberg Pharma AB. It contains detailed financial data for the period, including income statements, EBITDA, EBIT, and cash flow metrics for both the nine-month period and the third quarter. It also includes management commentary, business updates, and strategic outlooks. As it provides comprehensive financial results for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2025
2025-11-11 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – September 2025' for Moberg Pharma AB. It contains detailed financial data for the nine-month and third-quarter periods, including net revenue, EBITDA, EBIT, profit for the period, and earnings per share. It also includes management commentary, business updates, and operational highlights. Since it provides comprehensive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2025
2025-11-11 English
Moberg Pharma och Karo Healthcare ingår exklusivt licensavtal för MOB-015/Terclara i Europa, vilket driver tillväxt och marknadsexpansion
M&A Activity Classification · 100% confidence The document is a press release announcing a new exclusive licensing agreement between Moberg Pharma and Karo Healthcare for the commercialization of a pharmaceutical product (MOB-015/Terclara) in Europe. This type of strategic partnership announcement, which details business expansion and commercial strategy, falls under the category of general regulatory announcements or corporate news that does not fit into specific financial reporting categories like 10-K or Earnings Releases. Given the nature of the announcement as a corporate update regarding a business agreement, it is classified as a Regulatory Filing (RNS).
2025-11-05 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.